Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
company offering greater transparency and access to private market assets, today announces a strategic partnership with Apex Group Ltd. (“Apex Group”), a global financial services provider, to offer Valuation as a Service (“VaaS”) to clients worldwide.
Mondo Visione Contextual Ad
Through the partnership, Inveniam and Apex Group will use Inveniam’s patented blockchain technology and the Inveniam.io data operating system to deliver digitally credentialed, higher-functioning private asset data for more consistent, fully auditable valuations.
Traditionally valuing real estate, private equity, infrastructure, and private credit assets involved an opaque and time-consuming process. Inveniam.io’s use of blockchain and artificial intelligence increases trust in the underlying data and provides a fully auditable data trail for permissioned users without the need for asset owners to relinquish control of their own data.
Inveniam.io credentials the underlying documents which form the basis for private asset valuations, extracts relevant data from those documents, and provides real-time access to third-party valuation providers in a format that can increase the speed and reliability of the valuation process. Inveniam’s solution provides the trusted data layer which can enable private market assets to trade more efficiently in secondary markets, increasing liquidity.
“Public markets thrive because of trusted infrastructure and wide access to information for investors,” says Patrick O’Meara, Chief Executive Officer of Inveniam. “Our technology and our strategic partnership with Apex Group will allow us to revolutionize the private markets by bringing a new level of trusted information, price discovery and transparency to private markets. We are setting a new global standard for trusted private market data.”
“As allocations to private asset classes continue to grow, trusted data is essential to being able to transact in private market assets. Using data that is verified on blockchain, through our innovative partnership with Inveniam will create efficiencies and deliver benefits for the $3 trillion of client assets we service,” comments Georges Archibald, Chief Innovation Officer & Regional Head of North America, Apex Group.
Leap makes up 1/3rd NAV being sold for current MCAP
Remaining NAV (current value £12 million) focused on cannabis (specifically EU market) and Germany announcing cannabis legalisation and U.S. in lockstep the future is bright. £6m of the NAV is concentrated on the huge German market. Throw in Juvenescence raising serious money pre-IPO (Lygenesis growing human liver in end stage patients the obvious catalyst) and Inveniam having on-boarded $25 billion in assets to their platform (rising exponentially in the short-term -Apex Group who led their series A have $3 trillion in assets they want to onboard to the Inveniam platform) represents excellent value at current price.
https://twitter.com/greenhamneggs/status/1585556213852413960?s=46&t=3XDbcZcpaloEtLjkZZXEQw
Avextra maintains an exclusive, long-term contract and manufacturing agreement for cannabis products with Dr. Reckeweg & Co. GmbH. The EU-GMP certified German pharmaceutical company has over 75 years of experience in manufacturing plant-based medicines.
The CEO of Dr. Reckeweg is also on the board of avextra along with Alfredo Pascual VP of Investments at Seed Innovations who is a Board advisor.
The CEO of Dr Reckeweg is also the President of ECHAMP (the European Coalition on Homeopathic & Anthroposophic Medicinal Products.
Avextra have both a cannabis distribution license in Germany as well as a Germany cannabis manufacturing license, a U.K. license to open Medicinal Cannabis Clinics and of course like all the Seed investments are EU-GMP compliant.
I keep telling you all Germany calling..
For good reason. See every major cannabis play chart, knock each and everyone of them back to all time chart..
What do you see? A monster spike when Canada announced recreational cannabis. A tiny country (by population) of 38 million people.
Whatever happens in Germany eventually happens to the whole of Europe..450 million people comprising the largest cannabis market in the World.
We have £6m of NAV (with a mcap a sniff above £5m) tied up in LGP & Eurox.
LGP
LGP now has medicinal cannabis supply agreements with four key wholesalers and distributors in Germany, including three of the four largest independent, own-brand medicinal cannabis distributors in the country
Agreement extends LGP’s lead as the pre-eminent non-Canadian global medicinal cannabis group supplying products into Germany and the EU
Agreement represents continued validation of LGP’s key strategy of developing bespoke, high-value white label strains for export to lucrative jurisdictions
Avextra
Eurox is a German company and were the first to launch ‘Made In Germany’ Cannabis Derivatives Into the German Domestic Market.
Its ambition is to secure between 10 to 20% of the domestic derivatives market which accounts for 50% of the total German market.
Eurox Chairman Neil Smith added: “Our ambition is to take up to 20% of the market. Our USP is ‘Made in Germany’. We are the only German derivatives company operating in cannabis, capable of doing that.
“We will be selling high-quality medicines from a high-quality jurisdiction. There is a need for more domestic products in Germany with the country over-reliant on imports. “
Eurox is working with wholesale domestic partners and its own sales team to deliver products to the nation’s 20,000-plus pharmacies.
These partners include some of the established five major pharmaceutical distributors as well as some of the emerging handful of cannabis wholesalers and, a further 50-or-so wholesalers, looking to break into the cannabis space.
Enough of my idle chatter. Without news Seed is undervalued relative to NAV of 350%.
The Germany news is a monster
https://www.bbc.co.uk/news/world-europe-63404181.amp
Germany calling